Alcon acquires Neurotech for USD 550m, gaining ENCELTO, the only FDA-approved MacTel type 2 cell therapy. Read how it expands Alcon's retina portfolio.

Curis prices an $8.5M private placement at $0.51 per share to fund emavusertib CLL data in December 2026. Read the full story on the offering and runway.

Novartis's Cosentyx is now approved in Europe for polymyalgia rheumatica, the first IL-17A inhibitor for this use. Read the full story to learn more today.

Pennsylvania court awards Inovio $80.4M in breach-of-contract case over DNA plasmid supply deal with VGXI and GeneOne. Read the full ruling details now.

Roivant and Priovant report brepocitinib met the primary endpoint in Phase III uveitis trials. Read the latest results and ...

Kyverna reports one-year Phase II data for miv-cel in stiff person syndrome and plans a rolling BLA filing. Read the full ...

Muna Therapeutics' oral TREM2 modulator MNA-001 showed no serious adverse events in Phase I. Read how the Phase II ...

Olorofim meets its non-inferiority goal against AmBisome in the Phase III OASIS trial for invasive aspergillosis. Read full ...

City Therapeutics (Nasdaq: CTY), a clinical-stage RNAi company, closed its upsized IPO raising $230M at $18 per share. Read ...

Rapport Therapeutics' RAP-219 met primary and secondary endpoints in a Phase II bipolar mania trial, cutting YMRS scores. See results and Phase III plans.

Disc Medicine's bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for EPP, setting up an NDA ...

Hologic signs deal to acquire Barcelona-based Reveal Genomics, expanding breast cancer diagnostics to complement its BCI test. Read the full deal details.